Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: A meta-analysis of randomized controlled trials

Peritoneal Dialysis International

Volumn 31, Issue 2, 2011, Pages 179-188

  Qi, Hualin ^a   Xu, Chen ^b   Yan, Haidong ^a   Ma, Jun ^b  

^a TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clinical outcomes; Icodextrin; Meta analysis; Systematic review

Indexed keywords

CREATININE; GLUCOSE; ICODEXTRIN; NITROGEN; UREA; DIALYSIS FLUID; GLUCAN; HEMODIALYSIS FLUID;

ADULT; ADVERSE OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSATE LEVEL; FEMALE; GLOMERULUS FILTRATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT WITHDRAWAL; UPREGULATION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

BIOLOGICAL TRANSPORT; DIALYSIS SOLUTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCANS; GLUCOSE; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80051519665     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2009.00264     Document Type: Review

References (39)

1. Nolph KD, Ryan L, Moore RH, Legrain M, Mion C, Oreopoulos DG. Factors affecting ultrafiltration in continuous ambulatory peritoneal dialysis. Perit Dial Bull 1984; 4:14-19.
2. Henderson LW, Leypoldt JK. Ultrafiltration with peritoneal dialysis. In: Nolph KD, ed. Peritoneal Dialysis, 3rd ed. Dordrecht: Kluwer Academic Publishers; 1989: 117-32.
3. Krediet R, Boeschoten E, Zuyderhoudt F, Arisz L. The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis. Clin Nephrol 1987; 27:51-5.
4. Rippe B, Stelin G, Haraldsson B. Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 1991; 40: 315-25.
5. Pollock CA, Ibels LS, Caterson RJ, Mahony JF, Waugh DA, Cocksedge B. Continuous ambulatory peritoneal dialysis: eight years of experience at a single center. Medicine (Baltimore) 1989; 68:293-308.
6. Slingeneyer A, Canaud B, Mion C. Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis: an epidemiological study. Nephron 1983; 33:133-8.
7. Heimbürger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal fluid transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
8. Hain H, Kessel M. Aspect of new solutions for peritoneal dialysis. Nephrol Dial Transplant 1987; 2:67-72.
9. Ha H, Yu MR, Choi HN, Cha MK, Kang HS, Kim MH, et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 2000; 20(Suppl 5):S10-18.
10. Diazo-Buxo JA, Farmer CD, Chandler JT, Walker PJ, Burgess WP. CCPD-"wet" is better than dry [Abstract]. Perit Dial Bull 1987; 7:S22.
11. Twardowski ZJ, Khanna R, Nolph KD. Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 1986; 42: 92-101.
12. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17:84-7.
13. Coles GA. Biocompatibility and new fluids. Perit Dial Int 1999; 19(Suppl 2):S267-70.
14. Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Int 2000; 20(Suppl 5):S48-56.
15. Chung SH, Stenvinkel P, Bergstrom J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 2000; 20(Suppl 5): S57-67.
16. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002; 31:140-9.
17. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.7. In: The Cochrane Library, Issue 3. Chichester: United Kingdom: Wiley & Sons; 2005.
18. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int 2000; 20(Suppl 2):S106-13.
19. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550-3.
20. Posthuma N, ter Wee PM, Donker AJ, Peers EM, Oe PL, Verbrugh HA. Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 1998; 13:2341-4.
21. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int 1995; 15:226-30.
22. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496-503.
23. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546-54.
24. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-44.
25. Konings CJ, Schonck M, Wirtz J, Gerlag PG, Wolters J, Leunissen KM. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-63.
26. Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-65.
27. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862-71.
28. Lin A, Qian J, Li X, Yu X, Liu W, Sun Y, et al. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol 2009; 4:1799-804.
29. Paniagua R, Ventura MJ, Avila-Díaz M, Cisneros A, Vicenté-Martínez M, Furlong MC, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009; 29: 422-32.
30. Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int Suppl 2002; 81:S72-9.
31. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17:2591-8.
32. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24:2909-14.
33. Wang AYM. The "HEART" of peritoneal dialysis: residual renal function. Perit Dial Int 2007; 27:116-24.
34. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15:1061-70.
35. Krediet RT, Ho-dac-Pannekeet MM, Imholz AL, Struijk DG. Icodextrin's effects on peritoneal transport. Perit Dial Int 1997; 17:35-41.
36. Woodrow G, Stables G, Oldroyd B, Gibson J, Turney JH, Brownjohn AM. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant 1999; 14:1530-5.
37. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000; 15:862-6.
38. Queffeulou G, Bernard M, Vrtovsnik F, Skhiri H, Lebrun Vigne B, Hufnagel G, et al. Severe cutaneous hypersensitivity requiring permanent icodextrin withdrawal in a CAPD patient. Clin Nephrol 1999; 51:184-6.
39. Lam-Po-Tang MK, Bending MR, Kwan JT. Icodextrin hypersensitivity in a CAPD patient. Perit Dial Int 1997; 17:82-4.